stockrowLexicon Pharmaceuticals, Inc.
LXRX Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024.
- Revenue
- −20.7%
- EPS
- +21.3%
- Free cash flow
- +66.1%
- Total debt
- −8.17%
Quarter to September 2026, against a year earlier
Follow LXRX
Alert me
Lexicon Pharmaceuticals, Inc. (LXRX) EV/Sales
As of 6 November 2026, Lexicon Pharmaceuticals, Inc. (LXRX) trades at a EV/Sales of 17.4×. Over the past ten years it has ranged from −1.4× (March 2025) to 4,793× (May 2023); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.5× | 133.15% |
| FY2024 | 3.2× | (98.62%) |
| FY2023 | 235× | (86.49%) |
| FY2022 | 1,736× | 5.71% |
| FY2021 | 1,642× | 16,384.30% |
| FY2020 | 10.0× | 674.47% |
| FY2019 | 1.3× | (89.68%) |
| FY2018 | 12.5× | 14.27% |
| FY2017 | 10.9× | (29.72%) |
| FY2016 | 15.5× | 110.06% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 18.4× | (16.60%) |
| Jun 2026 | 22.1× | 202.75% |
| Mar 2026 | 7.3× | (3.20%) |
| Dec 2025 | 7.5× | 12.85% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| ATTO Attovia Therapeutics, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | 1.5× |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 4.0× |
| OABI OmniAb, Inc. compare | 14.5× |
| LXRX Lexicon Pharmaceuticals, Inc. | 17.4× |
| SLDB Solid Biosciences Inc. compare | 57.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)